secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001157523-22-000999
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q2 revenue $973.1M (+6.4% YoY); non-GAAP EPS $2.77 (+6.1%); cuts FY22 guidance
--------------------------------------------------------------------------------

- GAAP EPS $2.13 vs $1.72 Q2 2021; non-GAAP EPS $2.77 vs $2.61.
- Revenue $973.1M, organic growth 9.5% led by DSA and RMS segments.
- FY22 guidance cut: organic rev growth 10-12% (prev 12.5-14.5%), non-GAAP EPS $10.70-$10.95 (prev $11.50-$11.75).
- DSA segment revenue $591.9M (+12.9% organic); operating margin improved to 25.3% non-GAAP.
- Manufacturing segment revenue $194.8M (-1.5%); CDMO weakness offset by Biologics Testing growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000115752322000999/0001157523-22-000999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000115752322000999/a52799763.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer